Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on October 14, 2019. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Diane Parks as a Class III director, effective October 14, 2019. Her term expires at the 2020 annual meeting of stockholders. No other material changes to the company's operations or financial status are disclosed in this document.
Management Commentary and Compensation Details
Under the Company's Amended and Restated Non-Employee Director Compensation Policy, Ms. Parks received the following compensation upon appointment:
- Annual Cash Retainer: $38,000 for service on the Board.
- Initial Option Grant: 30,000 shares of common stock, vesting annually over a three-year period.
- Additional Option Grant: 8,666 shares of common stock, vesting in full on the one-year anniversary of the grant date.
- Future Grants: Automatic annual option grants to purchase 13,000 shares on the date of each annual meeting, vesting in full one year after the grant date.
All option grants vest in full in the event of a change in control. Ms. Parks has also entered into the Company's standard Indemnification Agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 38,666 new options granted to Ms. Parks.
- Confirm the vesting schedule details for the 30,000 shares (annual vesting) versus the 8,666 shares (one-year cliff).
- Review the Company's equity incentive plan to understand the specific definition of "change in control" triggering full vesting.
- Check subsequent filings for the 2020 annual meeting to confirm Ms. Parks' re-election or continued tenure.